JAK3 deregulation by activating mutations confers invasive growth advantage in extranodal nasal-type natural killer...

Area of Science:

• Oncology
• Molecular Biology
• Immunology

Background:

• Extranodal, nasal-type natural killer (NK)/T-cell lymphoma (NKCL) is an aggressive cancer with a poor prognosis.
• Constitutive activation of signal transducer and activator of transcription 3 (STAT3) is a common oncogenic event in NKCL.

Purpose of the Study:

• To investigate the upstream mechanisms driving STAT3 activation in NKCL.
• To evaluate the therapeutic potential of targeting the Janus kinase 3 (JAK3)/STAT3 pathway in NKCL.

Main Methods:

• Analysis of JAK3 phosphorylation and mutations in NKCL cell lines and primary tumors.
• In vitro studies using JAK3 inhibitors and small-interfering RNAs to assess effects on NKCL cell growth and survival.
• In vivo studies using a human NKCL xenograft mouse model treated with a JAK3 inhibitor.

Main Results:

• Constitutive JAK3 phosphorylation at tyrosine 980 was observed in most NKCL samples, leading to STAT3 activation.
• Acquired mutations in the JAK3 pseudokinase domain were identified in a subset of NKCL tumors.
• Inhibition of JAK3 significantly reduced NKCL cell growth and survival in vitro and delayed tumor growth in vivo.

Conclusions:

• Constitutive JAK3 activation, often driven by mutations, is a frequent and critical event in NKCL pathogenesis.
• The JAK3/STAT3 pathway is a key driver of NKCL cell proliferation, survival, and invasion.
• Targeting JAK3 represents a promising therapeutic strategy for NKCL.